Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/11307
Title: Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias.
Authors: Villemagne, Victor L;Ong, Kevin;Mulligan, Rachel S;Holl, Gerhard;Pejoska, Svetlana;Jones, Gareth;O'Keefe, Graeme J;Ackerman, Uwe;Tochon-Danguy, Henri;Chan, J Gordon;Reininger, Cornelia B;Fels, Lueder;Putz, Barbara;Rohde, Beate;Masters, Colin L;Rowe, Christopher C
Affiliation: Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia. villemagne@petnm.unimelb.edu.au
Issue Date: 15-Jul-2011
Citation: Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 2011; 52(8): 1210-7
Abstract: Amyloid imaging with (18)F-labeled radiotracers will allow widespread use, facilitating research, diagnosis, and therapeutic development for Alzheimer disease. The purpose of the study program was to compare cortical amyloid deposition using (18)F-florbetaben and PET in controls and subjects with mild cognitive impairment (MCI), frontotemporal lobar degeneration (FTLD), dementia with Lewy bodies (DLB), vascular dementia (VaD), Parkinson disease (PD), and Alzheimer disease (AD).One hundred nine subjects in 3 clinical studies at Austin Health were reviewed: 32 controls, 20 subjects with MCI, and 30 patients with AD, 11 with FTLD, 7 with DLB, 5 with PD, and 4 with VaD underwent PET after intravenous injection of 300 MBq of (18)F-florbetaben. Standardized uptake value ratios (SUVR) using the cerebellar cortex as a reference region were calculated between 90 and 110 min after injection.When compared with the other groups, AD patients demonstrated significantly higher SUVRs (P < 0.0001) in neocortical areas. Most AD patients (96%) and 60% of MCI subjects showed diffuse cortical (18)F-florbetaben retention. In contrast, only 9% of FTLD, 25% of VaD, 29% of DLB, and no PD patients and 16% of controls showed cortical binding. Although there was a correlation between Mini Mental State Examination and β-amyloid burden in the MCI group, no correlation was observed in controls, FTLD or AD.(18)F-florbetaben had high sensitivity for AD, clearly distinguished patients with FTLD from AD, and provided results comparable to those reported with (11)C-Pittsburgh Compound B in a variety of neurodegenerative diseases.
Internal ID Number: 21764791
URI: http://ahro.austin.org.au/austinjspui/handle/1/11307
DOI: 10.2967/jnumed.111.089730
URL: http://www.ncbi.nlm.nih.gov/pubmed/21764791
Type: Journal Article
Subjects: Aged
Aged, 80 and over
Alzheimer Disease.radionuclide imaging
Amyloid beta-Peptides.metabolism
Aniline Compounds.pharmacology
Case-Control Studies
Cerebellum.radionuclide imaging
Dementia.radionuclide imaging
Female
Fluorine Radioisotopes.pharmacology
Frontotemporal Dementia.radionuclide imaging
Humans
Image Processing, Computer-Assisted
Lewy Bodies.radionuclide imaging
Male
Middle Aged
Neurodegenerative Diseases.radionuclide imaging
Positron-Emission Tomography.methods
Radioisotopes.pharmacology
Stilbenes.pharmacology
Treatment Outcome
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.